



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 5:

C12Q 1/68

(11) International Publication Number: WO 92/16657

(43) International Publication Date: 1 October 1992 (01.10.92)

(21) International Application Number:

PCT/US92/01691

(22) International Filing Date:

12 March 1992 (12.03.92)

(30) Priority data:

669,568

13 March 1991 (13.03.91) US

(60) Parent Application or Grant

(63) Related by Continuation US

669,568 (CIP)

Filed on

13 March 1991 (13.03.91)

(71) Applicant (for all designated States except US): E.I. DU PONT DE NEMOURS AND COMPANY [US/US]; 1007 Market Street, Wilmington, DE 19898 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): LIVAK, Kenneth, J. [US/US]; 2418 Shellpot Drive, Wilmington, DE 19803 (US). RAFALSKI, Jan, Antoni [US/US]; 2028 Long-come Drive, Wilmington, DE 19810 (US). SHEPHERD, Nancy, Faye, Stacy [US/US]; 210 Partridge Way, Kennett Square, PA 19348 (US).

(74) Agent: GALLEGOS, R., Thomas; E.I. du Pont de Nemours and Company, Legal/Patent Records Center, 1007 Market Street, Wilmington, DE 19898 (US).

(81) Designated States: AT (European patent), BE (European patent), CA, CH (European patent), DE (European patent), DK (European patent), ES (European patent), FR (European patent), GB (European patent), GR (European patent), IT (European patent), JP, LU (European patent), MC (European patent), NL (European patent), SE (European patent), US.


Published

With international search report.

(54) Title: METHOD OF IDENTIFYING A NUCLEOTIDE PRESENT AT A DEFINED POSITION IN A NUCLEIC AC-

(57) Abstract

A method is described for identifying a nucleotide at a defined point on a nucleic acid sequence. An oligonucleotide probe is annealed to a target nucleotide sequence of the nucleic acid sample at a point immediately adjacent and 3' to the nucleotide of interest. The probe is then extended in the direction of the nucleotide of interest in a reaction medium containing at least one chain terminating nucleotide triphosphate (ATP, GTP, TTP and CTP). The nucleotide of interest is complementary to the labeled nucleotide incorporated into the primer by the extension reaction.



10

15

20

25

30

TITLE

METHOD OF IDENTIFYING A NUCLEOTIDE PRESENT AT A DEFINED POSITION IN A NUCLEIC ACID FIELD OF THE INVENTION

This invention relates to a rapid, convenient process to identify a nucleotide present at a specific position in a nucleic acid chain (DNA or RNA) of a biological sample.

BACKGROUND OF THE INVENTION

The nucleic acid content of any organism is the essence of that organism, and differences in the nucleic acid are known to be of primary importance in distinguishing one from another. The science of genetics is based on the identification and characterization of differences in nucleic acid sequence. These differences, or polymorphisms, are often termed "mutations" and may be due to nucleotide substitution, insertion or deletion. Thus, many techniques have been developed to compare homologous segments of DNA or RNA to determine if the segments are identical or if they differ at one or more nucleotides. Identification of genetic polymorphisms is useful for genetic diagnoses in medicine, identification of individuals in forensic science, identification of pathogenic organisms, construction of genetic polymorphism maps for locating genes important in disease and in agriculture and for breeding of plants and animals.

The most definitive method for comparing DNA segments is to determine the complete nucleotide sequence of each segment. Examples of how sequencing has been used to study mutations in human genes are included in the publications of Engelke, et. al., Proc.

detection in a genomic DNA sample is very labor intensive for it requires preliminary steps of genomic DNA isolation, restriction, gel electrophoresis and Southern transfer steps, before hybridization to a probe that is generally radioactively labeled for sensitive detection of homologous sequences. A major problem associated with RFLP detection is the necessity of the polymorphism to affect cleavage with a restriction endonuclease, therefore many mutations cannot be detected with this method (Jeffreys, Cell 18:1-18, 1979). More importantly, although RFLP and several other methods in the prior art (e.g. Wallace et al., Nucl. Acids Res. 9:879-894, 1981 or Saiki, et al., U.S. Pat. No. 4,683,194 or Kornher et al., U.S. Pat. No. 4,879,214) are useful for finding polymorphisms in DNA, they do not elucidate the exact nature of the nucleotide present at a specific position on the nucleic acid sequence. In some applications, such as prenatal diagnosis, knowledge of which nucleotide is present at a given position is extremely important, since some nucleotide changes do not alter the coding capacity of a gene and are therefore "silent" with respect to phenotype. Those techniques that elucidate the nature

10

15

20

Many techniques designed to elucidate the nature of a nucleic acid polymorphism involve hybridization with a polynucleotide probe, a portion of which is complementary to the nucleotide position(s) of interest. A target sequence that is perfectly complementary to the probe can be distinguished from a target that differs by as little as a single nucleotide in a variety of ways. A technique involving amplification and mismatch detection (AMD), described by Montandon et al., Nucl. Acids Res. 17:3347-3358, 1989, utilizes amplification of

20

25

30

Amplification Reaction (LAR) as reported by Wu and Wallace, Genomics 4:560-569, (1989) and Wallace and Skolnick (WO 89/10414) is also dependent upon ligation of oligonucleotides whose 3-prime ends include the nucleotide position of interest. They demonstrate that four pairs of oligonucleotides that are complementary to the upper and lower strand of the target DNA will be exponentially amplified only if there is perfect complementarity between the oligonucleotides and the 10 target DNA. The patent of Vary et al., U.S. Pat. No. 4,851,331, also depends upon an enzymatic reaction that requires one end of the oligonucleotide probe to form a perfect, complementary matched basepair with the target nucleotide sequence. As in the examples above, an oligonucleotide probe is designed such that the 3-prime end of the complementary probe includes the specific nucleotide position of interest. After annealing this oligonucleotide probe to the template DNA, a polymerase that replicates nucleic acid strands in a template directed fashion is used to incorporate modified nucleotides into a newly synthesized strand. If the 3prime end of the oligonucleotide probe did not contain a nucleotide complementary to the target nucleotide sequence, then the polymerase cannot begin the replication process. The amount of incorporation is a measure of the amount of the specific template, DNA in the biological sample. This same principle of utilizing a polymerase to discriminate whether there is a mismatched base at the 3-prime end of the primer was also recently combined with the PCR to give an exponential rather than linear increase of the reaction products in a process called Allele-specific Polymerase Chain Reaction (ASPCR) (Wu et al., Proc. Natl. Acad. Sci. 86:2757-2760, 1989). In their example, the

same result can occur if the assay method is too sensitive such that even inefficient ligation or replication is detected as a positive signal. Misincorporation of nucleotide substrate, well

- documented in the literature for polymerases; Ricchetti and Buc, The EMBO J. 9:1583-1593, (1990); or template-independent ligation products due to blunt end ligation; Hayashi et al., Nucl. Acids Res. 14:7617-7631, (1986); can lead to a false signal if not adequately suppressed
- in the reaction. Such misincorporation is especially apparent when the correct, complementary nucleotide substrate is absent from the reaction. The polymerase chain reaction is quite dependent upon products generated during the first few rounds of amplification.
- The difficulty of devising conditions that totally suppress amplification by the primer that contains a mismatched base at the 3' end is also documented in Chehab and Kan; Proc. Natl. Acad. Sci. 86:9181 (1989); where fluorescence values as high as 0.8 were considered negative for they were less than 1.0, while all values

above 1.0 were considered positive for amplification (even values as low as 1.4 were considered positive).

In the technique described in Mundy, U.S. Pat. No. 4,656,127, specific mutations can be detected by first hybridizing a labeled DNA probe to the target nucleic acid in order to form a hybrid in which the 3! end of

the probe is positioned adjacent to the specific base being analyzed. Then, a DNA polymerase is used to add a nucleotide analog, such as a thionucleotide, to the probe strand, but only if the analog is complementary to the specific base being analyzed. Finally, the probetarget hybrid is treated with exonuclease III. If the nucleotide analog has been incorporated, the labeled probe is protected from nuclease digestion. Absence of

15

The present invention solves several problems inherent in the Sokolov method. (1) This invention is not dependent upon radioactive substrates nor the timeconsuming monitoring of the assay via a polyacrylamide gel and subsequent autoradiography. (2) This invention uses chain-terminating nucleotides as substrates in the reaction, therefore preventing incorporation of several of the same nucleotide in the primer extension product if there are several of the same nucleotides present in a row on the template. (3) The analysis of Sokolov required four separate reactions whereas the present invention would need only one reaction to gain the same amount of information. (4) As mentioned above, if the correct, complementary nucleotide substrate is not present in the reaction, then significant misincorporation can occur in the Sokolov reaction. Misincorporation is substantially prevented in the present invention.

Automation of the ASPCR reaction was described but not demonstrated in Wu et al., Proc. Natl. Acad. Sci. 20 86:2757-2760, (1989), and again by Chehab and Kan, Proc. Natl. Acad. Sci. 86:9178-9182, (1989), for fluorescent In both cases, each ASPCR reaction is performed using one biotin-labeled primer and one fluorescentlylabeled primer. The biotinylated, double-stranded 25 amplification products are then separated from unincorporated fluorescent primer using streptavidin coated magnetic beads. The color of the amplified DNA would then be determined fluorometricly through a fiber optic bundle, or alternatively, by separation and 30 detection on a sequencing gel as is currently performed for DNA sequencing using fluorescently labeled primers. The differences between this method and that of the present invention are significant. Most importantly,

15

20

25

30

to automation due to the lack of centrifugation steps and the ability to quickly assay reaction products without a gel separation step. If a gel separation assay is used, then multiplexing of samples based on differences in length of the probe oligonucleotide is possible. Alternatively, the probe oligonucleotide of several reactions can be of the same length, but loaded at different times after pausing the electrophoresis run.

SUMMARY OF THE INVENTION

The present invention provides a process for identifying the nucleotide present at a specific position in a nucleic acid sequence. It is based upon the selective attachment of one of four chainterminating nucleotides, that are detectably labeled and distinguishable, onto a probe in a complementary, template dependent fashion. The probe is designed to selectively hybridize to a target nucleotide sequence and oriented such that a one nucleotide extension of the probe, usually in the 3-prime direction, will base pair to the nucleotide position of interest. The oligonucleotide probe, the nucleic acid containing the target nucleotide sequence, or both, may contain a site for specific immobilization to facilitate separation from unincorporated nucleotides and primers, such that the labeled nucleotides incorporated into the reaction product can be measured without use of a gel system such as agarose or acrylamide.

Thus the present invention provides a method for the identification of the nucleotide present at a single, defined position in the nucleic acid which comprises the following steps:

(a) contacting a nucleic acid analyte with a probe oligonucleotide of sufficient length and appropriate

DESCRIPTION OF FIGURES

Figure 1, comprising Figures la-lh, illustrate in various schematic forms, the location of various components of the process of this invention.

Figure la illustrates an analyte strand (An) which contains the nucleotide position of interest (N), the identity of which is to be determined by the assay. A target nucleotide sequence (TNS) immediately 3' of, but not including the nucleotide position of interest is illustrated. A double strand nucleic acid region forms when a probe binds to analyte strand An by complementary base pairing to the target nucleotide sequence TNS.

Figure 1b illustrates the incorporation of a chain terminating nucleotide (N*) complementary to the

15 nucleotide of interest (N) after contacting the double stranded region in Figure 1a with a polymerase capable of primer extension. (The * in this and subsequent figures is used to illustrate a detectable label attached to the nucleotide).

Figure 1c illustrates the same features as Figure 1a, but with a specific example showing the nucleotide of interest as a thymidine (T).

Figure 1d illustrates the same features as Figure 1b, but using the same specific example as Figure 1c, to show the result of enzymatic incorporation of a detectably labeled adenosine at the 3' terminus of the probe as the nucleotide complementary to the nucleotide of interest (thymidine).

Figure le illustrates the incorporation of a

detectably labeled guanosine at the 3' terminus of the probe and complementary to the nucleotide of interest (cytidine).

Figure 1f illustrates the use of another analyte strand for the assay (the complementary strand of the

examples are detected with the Genesis 2000 DNA analysis system.

Figure 7a illustrates the output signal [ratio of the green line to red line peak height, +/- one standard deviation] of data obtained as in Figure 7b and 7c for each of the four detectably labeled nucleotides used in the examples detected either through a gel or through a capillary.

Figure 7b is representative data showing the

10 position and relative peak heights of the two
photomultiplier tube signals (red and green lines) when

SF-ddGTP-505 or SF-ddTTP-526 are electrophoresed through
a urea-polyacrylamide slab gel mounted on the Genesis

2000.

Figure 7c illustrates the output signal obtained when SF-ddGTP-505 or SF-ddCTP-519 are each passed four times (therefore four peaks) through an empty capillary mounted for detection on the Genesis 2000 unit.

Figure 8 illustrates the double stranded portion of 20 the mouse RNA polymerase II gene that was amplified using PCR primer 1 and PCR primer 2, as well as the position and sequence of the various oligonucleotide probes used in Examples 1-5.

Figure 9 illustrates the sequence of the Wildtype 25 and the Mutant allele of the RNA polymerase II gene between nucleotides 5395 and 5454, with the difference between the two alleles indicated by boldface type at position 5430.

Figure 10 illustrates the data obtained in Example

1: Incorporation of either labeled SF-ddATP-512, SFddGTP-505, or both in approximately equal amounts, when
probe A is used on nucleic acid samples known to be
either Wildtype, Mutant, or Heterozygous at nucleotide
position 5430 of the RNA polymerase II gene.

biological sample with respect to specific, nucleic acid sequence information (e.g. nucleotide positions correlated with phenotypic differences among individuals between species or in tissues). Single base pair mutations such as transitions, transversions, insertion, deletion as well as more complex rearrangements can be assayed using the method of the present invention if the appropriate oligonucleotide probe is designed (Figure 5).

10 The presence of a target nucleic acid in a biological sample may be detected generally as the presence or absence of an incorporated nucleotide. Individual nucleotides located at selected sites in the nucleic acid sample may also be identified. The method presented here is generally applicable to all nucleic 15 acid sequences (DNA or RNA), whether they are single or double stranded, as long as the target nucleic acid strand is of sufficient length to form a hybrid with a complementary, oligonucleotide probe. Any source of nucleic acid, in purified or nonpurified form can be 20 utilized as the starting nucleic acid or acids, if it contains, or is suspected of containing, the target nucleic acid sequence. The target nucleic acid can be only a fraction of a larger molecule or can be present initially as a discrete molecule. Additionally, the 25 target nucleic acid may constitute the entire nucleic acid or may be a fraction of a complex mixture of nucleic acids.

The method of this invention requires formation of a hybrid between an oligonucleotide primer (referred to herein as the oligonucleotide probe) and the target nucleic acid sequence. Probes of relatively short length (e.g. 10-100 nucleotides) are preferred in that they can be chemically synthesized. The probe can consist of

15

20

25

30

interest. Similarly, amplification primers that are free in solution can be extended and provide incorporation at positions other than the position of interest. Various methods obvious to those skilled in the art of molecular biology are available for removing unincorporated nucleotides and primers. However, since we desire a method that is rapid and automatable, the preferred form of separation is one utilizing attachment of the amplified nucleic acid product to a solid support with subsequent washing steps. An avidin-biotin system is preferred.

The template may be RNA or DNA, and may be double or single stranded. If double stranded, it is necessary to denature the strands to allow hybridization between the template strand and the oligonucleotide probe. Methods for this denaturation and subsequent hybridization step are well known to those skilled in the art of sequencing. However, since it is well known that formation of the hybrid between the oligonucleotide probe and the nucleic acid strand containing the target nucleic acid sequence can be inhibited by the complementary, non-template strand, the preferred method is to physically separate the template and the nontemplate strand after a denaturation step. The template strand can either be the strand present on the solid support (Figure 2), or a strand that is free in solution (Figure 3).

By design of an appropriate probe and utilizing the appropriate nucleic acid strand as template, essentially all nucleotide positions, even those at the end of a linear nucleic acid molecule can be assayed (Figure 4). In practice, since amplification from a complex nucleic acid mixture will at times give several different amplification products, the preferred method is to

15

20

25

30

nucleotide addition by a DNA polymerase. For example, cleavage of DNA with many restriction enzymes generates 5' overhangs that are substrates for DNA polymerases. Also, there are 3' exonucleases that remove 3' nucleotides from double-stranded DNA, producing molecules with 3' recessed strands and 5' overhanging strands.

The hybridizing and extending steps can be performed in solution or in solid phase reactions. The detection can also be in solution, after attachment to a solid phase, or after passing through a gel such as acrylamide or agarose. However, as previously mentioned, the first two methods are preferred for they avoid the time-consuming gel assay. Without a gel assay, it is necessary to separate the unincorporated labeled chain-terminators after the elongation step. Note that in the present invention, it is not necessary to wash away the excess oligonucleotide probe that did not hybridize, since the unextended probe does not contain a label.

There are four general forms of such separation: (1) immobilizing the elongated probe or hybrid selectively (e.g. by attaching to a binding segment on the analyte strand or on the probe) and separating away unincorporated, labeled nucleotide substrate together with sample polynucleotides that probe did not bind to; (2) immobilizing the elongated probe or hybrid non-selectively with other polynucleotides and separating away the unincorporated, labeled nucleotide substrate; (3) separating the unincorporated, labeled nucleotide substrate without immobilizing the elongated probe or hybrid, and (4) inactivating the label associated with unincorporated nucleotide substrate such that it is no longer detectable by the assay method employed.

present method should be independent of the binding system used to attach detectable label to the modified nucleotides during the detection step.

Crucial to this invention, are the chainterminating, detectably labeled nucleotide substrates. Detectably labeled does not mean that the detectable signal must be present at the time of incorporation. The fluorescent substrates described below require activation. Detectably labeled does not necessarily 10 mean that the nucleotide substrates carry a reporter such that there is not only the ability to detect the label, but also to identify the nucleotide. If only one nucleotide is present in the reaction, then detection of incorporation is sufficient for identification. 15 modified dideoxy-nucleotide substrates described in Prober et. al (EP-A 252683) or the DyeDeoxy terminators (a trademark of Applied Biosystems, Inc., Foster City, California) are examples of chain-terminating detectably labeled nucleotide substrates. However, unlike sequencing using fluorescently labeled chain-terminating 20 nucleotides, there is essentially no requirement in this method that each of the modified nucleotides have a similar mobility shift when run on a sequencing gel. the preferred embodiment, four chain-terminating nucleotides that are distinguishably labeled are present in each reaction. The need for four different labels is eliminated if the number of reactions per sample are increased (Figure 6). Unlike reports in the prior art, all four chain-terminating nucleotides may be present in 30 the initial reaction, but only one must be detectably labeled. Unlike nucleic acid sequencing using chain terminators, the chain-elongating dNTP substrates are not a component of the reaction of the present invention.

15

The present invention is further illustrated by reference to Figures 1-6.

In Figure 1a, an analyte strand (An) contains a nucleotide position of interest (N), the identity of which is to be determined by the assay, is defined as the first base of the analyte nucleic acid strand which is beyond the 5' end of the target nucleotide sequence in the 3' to 5' direction. A probe polynucleotide is produced as a reagent having a binding region complementary to the target nucleotide sequence (TNS). In this particular embodiment, the probe polynucleotide consists only of that complementary sequence; in other embodiments, the probe is extended in the 5' direction in a manner that does not interfere with the recognition and complementary base pairing to the target nucleotide sequence. The diagram in Figure 1a illustrates the double stranded nucleic acid region which forms when the probe binds to analyte strand An by complementary base pairing to the target nucleotide sequence TNS.

By contacting the double stranded region shown in 20 Figure la with a DNA polymerase specific therefore, the 3' end of the probe will be utilized as a primer and elongated opposite the analyte strand An which serves as a template for nucleotide incorporation. As illustrated 25 in Figure 1b, the nucleotide incorporated (N*) will be complementary to the nucleotide position of interest (N). In all illustrations, the * symbol is used to illustrate a detectable label attached to the nucleotide. The enzyme, primer and nucleic acid analyte 30 are chosen together such that a nucleotide complementary to the target nucleotide of interest is incorporated. For example, if analyte strand An is DNA, then a reverse transcriptase, a primer dependent prokaryotic DNA polymerase (e.g. the Klenow fragment of E. coli DNA

streptavidin complex, and rinsing away the unbound material. The two strands are then denatured (e.g. by addition of NaOH) and only the template strand is retained for the reaction. In Figure 2 the immobilized template strand is rinsed, while in Figure 3 the soluble, eluted strand is used as template after neutralizing the NaOH solution. The probe oligonucleotide is then hybridized to the template strand and the hybridized probe is elongated by addition 10 of a single, chain terminating nucleotide. The enzyme utilized in the reaction is a DNA polymerase such as reverse transcriptase and all four chain terminating nucleotides may be present, although only one must be detectably labeled. The unincorporated nucleotides are 15 removed from the reaction by washing. Note that in Figure 3, the template strand was not previously immobilized, so the probe oligonucleotide can now be captured onto solid support for efficient washing. nature of the label present on the elongated primer may 20 be measured directly after efficient removal of the unincorporated substrate. That is, the primer may still be bound to the solid support, either directly as shown in Figure 3 or indirectly through the hybrid formed with the analyte strand (Figure 2 without the final 25 denaturation step). For the particular brand of streptavidin coated magnetic beads used in our examples, the labeled primer is released from the beads after heating in the presence of formamide and EDTA. The magnetic beads do not interfere with standard gel 30 electrophoresis although they are loaded into the sample well along with the sample. If the sample is assayed through a capillary, then the beads may obstruct flow

and should be removed.

Conclusion: Since the other nucleotides were not detected, only T is present at the nucleotide of interest. No other reactions are required.

5

10

20

25

Method 2

All possible nucleotide substrates are present in each reaction but perhaps only 2 can be detectably labeled such that they are distinguishable from each other.

Result: Only ddATP* is incorporated and detected.

15 Conclusion: **T** is present at the nucleotide position, and **C** is not present. But do not know if either G or A are present.

2nd Reaction: provide substrates ddCTP*, ddTTP*, ddATP, ddGTP.

Result: There was no detectable incorporation.

Conclusion: G or A are not present at the position of interest.

(To provide evidence to support this further, one could use the same substrate mixtures except monitor the incorporation using the complementary strand as the anlayte and the different, but appropriately positioned primer.)

Method 3

All possible nucleotide substrates are present in each reaction but perhaps only one label is available for substrate labeling (e.g., the same as when radioactively labeled ddNTP's are utilized).

- 2. To illustrate that a single fluorescently labeled nucleotide can be incorporated in the assay using a commercially available enzyme preparation.
- 3. To illustrate that the unincorporated labeled substrate can be efficiently removed without timeconsuming centrifugation or column chromatography.
- 4. To illustrate the use of a DNA strand labeled at the 5' end with Biotin and bound to a solid support as the analyte strand.
- 10 5. To illustrate the ability to distinguish between three DNA samples by incorporation of an A (wildtype allele), a G (mutant allele), or both A & G (heterozygote) as the complementary nucleotide opposite the nucleotide position of interest.
- 6. To illustrate that the fluorescent nucleotide 15 substrates can be detected and distinguished on the Genesis 2000 DNA analysis unit either by gel electrophoresis or by passing the sample through a capillary.

25

<u>Definition of the Nucleotide Position of Interest:</u>

In this example, the nucleotide position of interest is that of the lower strand at nucleotide position 5430 of the mouse RNA polymerase II largest subunit gene as described by publication in the GenBank database, accession M12130 for the locus RO:Musrpolii2. A 602 nucleotide portion of this sequence from nucleotide 4915 to 5517 is illustrated in its double stranded form in Figure 8, with the nucleotide position of interest for 30 this example being at position 5430 on the lower strand (occupied by a bold-faced T in the sequence of the Wildtype allele which is shown in this Figure 8).

J. Corden and are as described in Bartolomei and Corden, Molec. and Cell. Biol. 7:586-594, 1987. The Wildtype and Mutant alleles are provided as bacterial strains containing the recombinant plasmids pE26-4 and pE26-7 respectively. The biological sample designated as Heterozygous is obtained as a cell line A21. DNA of each of the recombinant plasmids is prepared by standard molecular biology procedures (described in Sambrook et al., Molecular Cloning: A Laboratory Manual 1989), and genomic DNA is prepared from the A21 cell line as described in Corsaro and Pearson, Somatic Cell Genet. 7:603-616, 1981.

15 Amplifying a segment of DNA containing the nucleotide position of interest and the target nucleotide sequence:

As shown in Figure 8, the target nucleotide sequence and the nucleotide position of interest are within a 602 base pair segment of the RNA polymerase II gene. 20 copy number of this segment is increased using exponential amplification, using DNA of each of the three biological starting materials described above. The oligonucleotide primers used for PCR amplification of the region of interest in the RNA polymerase II gene are designated PCR amplification Primer 1 (5' CAGACATTTGAGAATCAAGTGAATCG 3') and PCR amplification Primer 2 (5' BCTCGGCTCTCAGGACCATAATCAT 3') where B-biotin (see Figure 8). They are synthesized by standard phosphoramidate chemistry on an Applied Biosystems DNA synthesizer. For the biotinylated 30 primer, the biotin moiety is added at the 5' end during synthesis as described in Cocuzza US patent 4,908,453. All such oligonucleotides used in this patent are prepared for the inventors by the Du Pont

25

30

stranded PCR amplification product contains a biotin moiety due to the biotin originally presnet on PCR amplification Primer 2. Thus, the separation is done by binding the biotinylated PCR amplification product to a streptavidin-coated solid support and rinsing away the non-biotinylated, PCR amplification Primer 1 and the unincorporated nucleotides. The support-bound PCR amplification product is then denatured using NaOH, the complementary, non-analyte strand is removed and the remaining analyte strand which is still bound to the solid support is rinsed and ready for the primer extension reaction. These steps are illustrated in the schematic drawing of Figure 2 and described below as steps 1-6.

- 1. Magnetic, streptavidin-coated beads from the Dynal corporation (Dynabeads M-280 Streptavidin, at 6 x 108 beads/ml) are washed and resuspended at the same concentration in Triton Wash Solution [0.17% (w/v) Triton X-100, 100 mM NaCl, 10 mM Tris-HCl pH7.5, 1 mM EDTA] essentially as described in the Application Brief 25 for the Genesis 2000 DNA analysis system.
 - 2. Approximately 20 μ l of double-stranded DNA template, amplified using PCR amplification with one of the two primers labeled with biotin, are mixed with 20 μ l of washed Dynabeads and incubated at 37°C for 30 minutes. This mixture is gently shaken intermitently in order to keep the magnetic beads in solution.
 - 3. After this incubation, the tube containing magnetic beads and DNA is placed near a magnet to draw the beads to one side of the tube. After approximately four minutes of magnetization, the supernatant is removed.
 - 4. The beads (with DNA bound) are then washed three times with TE buffer (10 mM Tris pH8, 1 mM EDTA) using

25

reaction. In this particular Example 2, it is as follows:

- 1 μ1 of 125 μM SF-ddGTP-505
- 1 μ l of 125 μ M SF-ddATP-512
- 5 0.5 μl Invitrogen Reverse Transcriptase (10μ/μl)
 - 10. The labeling reaction is at 42°C for 10 minutes, and then the reaction is placed on ice and 100 μl of TE is added.
- 10 11. The sample is again magnetized for 4 minutes and the supernatant removed, followed by 3 washes of 100 μ l TE buffer (magnetization between each wash) to remove unincorporated nucleotides.
- 12. The final supernatant is removed and the magnetic beads (with DNA bound) are resuspended in 6 μ l FE solution (95% formamide, 25mM EDTA) and stored -4°C until further use.

Detection of the chain terminating nucleotide attached to the probe:

- 13. The sample from step 12 is diluted 1:16 fold further in FE containing crystal violet, for easier visualization in loading the sample and to get the sample in a reasonable concentration for detection by slab gel electrophoresis on the Genesis 2000 DNA analysis system (methods as described by the instrument documentation, with a few parameters described in more detail below).
- 14. "Lane Finding" for the Genesis detection system is performed manually using a primer fluorescently labeled at the 3' end prepared in advance using terminal transferase and a fluorescent ddNTP as substrate as described in Trainor and Jensen, Nucl. Acids Res. 16:11846, (1988) that is electrophoresed into each

described in Prober et al. (1988) Science 238, 336-341. In brief, the chain terminators are distinguished by a ratio of the measured fluorescence from two photomultiplier tubes (PMT). Each PMT value is displayed as either a red or green mark on the output computer monitor, with a sample forming a peak as it passes by the excitory laser. (In the black and white Figures required for this patent application, the original color of each line of the sample peak is 10 indicated). Unlike the normal method of fluorescent base detection when multiple peaks of a sequencing reaction are being analyzed, the commercial Genesis 2000 software is unable to determine the identity of the fluorescent nucleotides (base call) in this application, for only a few peaks are present in the lane. It is 15 therefore necessary to prepare a one time calibration on the instrument by preparing a set of expected values for the fluorescently labeled chain terminators at various dilutions in FE (95% formamide, 25mM EDTA). important to note that the commercial instrument is 20 designed to have a non-linear response of the two PMTs when the voltage is too high. We experimentally determined that the ratio obtained for the green peak height to the red peak height for a given fluroescent 25 substrate is relatively invariant from experiment to experiment over the range of 0.1-9 volts. green to red ratio of a peak is only determined if the reaction samples are within this voltage range.

The result of such a calibration (+/- one standard deviation) is shown in Figure 7a by two different assay methods. The samples are either electrophoresed on a urea-polyacrylamide gel by standard gel electrophoresis procedures for the Genesis 2000, or syringe-loaded into a single, empty capillary (Part # TSP530700 from

and Het peak) are rerun at lower dilution (since the voltage of two of them are originally too high as shown in Figure 10a). The resulting sample peaks are displayed in Figure 10b with a smaller display window for easier measurement. In this example, the measured green/red ratios are as follows:

WT = 1.55 Mutant = 2.5 HET = 1.9

A comparison of these values to the calibration shown in Figure 7a illustrates that these ratios correspond to the expected incorporation of SF-ddATP-512 when the Wildtype allele is the source of the analyte strand, incorporation of SF-ddGTP-505 when the Mutant allele is the source of the analyte strand, and a mixture of both fluorescent nucleotides in approximately equal proportions when the analyte strand is derived from a heterozygous source (i.e. approximately equal number of Wildtype and Mutant analyte strands).

Identifying the nucleotide of interest as the nucleotide complementary to the chain terminating nucleotide which is added:

17. The nucleotide at the position of interest is 25 the nucleotide complementary to the nucleotide that is incorporated.

Therefore, the conclusion for the three samples of this example are as expected:

The reaction performed on the Wildtype allele

indicates that it does contain a thymidine (T) on the
lower strand at nucleotide position 5430 of the mouse
RNA polymerase II largest subunit gene, for the
nucleotide incorporated is SF-ddATP-512. The reaction
performed on the Mutant allele indicates that it does

Definition of the Target Nucleotide Sequence:

In this example, the target nucleotide sequence (TNS) is chosen as the 21 nucleotide sequence (5'ATGTAGAGGGCAAGCGGATCC3') that immediately flanks the nucleotide of interest such that the nucleotide position of interest is the next contiguous nucleotide in the 3' to 5' direction on that nucleic acid strand (see also Figure 1f).

10

15

5

The oligonucleotide probe:

In this example, the oligonucleotide probe consisted of the 21 nucleotide sequence 5' GGATCCGCTTGCCCTCTACAT 3' (probe B of Figures 8 and 9), and is perfectly complementary to the target nucleotide sequence defined above. Synthesis and purification is as described in Example 1.

Starting biological sample:

In this example, the claimed method will be illustrated using two of the same starting biological samples as described in Example 1: that of the Wildtype and Mutant. They are prepared as described in Example 1.

25

Amplifying a segment of DNA containing the nucleotide position of interest and the target nucleotide seguence:

The region of interest is amplified from the Wildtype and Mutant samples using methods as described in Example 1 with PCR amplification Primer 1 and PCR amplification Primer 2, except in this Example 2, the PCR amplification Primer 1 is biotinylated at the 5' end and the PCR amplification Primer 2 is not.

EXAMPLE 3

Aim:

- 1. To illustrate that under the conditions of Examples 1 and 2, that in some cases, the wrong nucleotide will be incorporated if the correct nucleotide is missing from the reaction (i.e. the problem with many of the assays discussed in the prior art is that of significant misincorporation in reactions where the correct nucleotide is not provided.
- 10 For this example, the same two reactions as described in Example 2 are performed with the following exceptions:
- a) For the reaction with the Wildtype allele in step 9 the SF-ddTTP-526 is omitted and the only fluorescent substrate in the reaction is 1 μ l of 125 μ M SF-ddCTP-519. (Unlabeled ddTTP is also absent in the reaction).
- b) For the reaction with the Mutant allele in step 9 the SF-ddCTP-519 is omitted and the only fluorescent substrate in the reaction is 1 μ l of 125 μ M SF-ddTTP-526. (Unlabeled ddCTP is also absent in the reaction).

The results shown in Figure 12 illustrate that for the Wildtype allele (upper panel), there is no

25 significant misincorporation of SF-ddCTP-519 as a complementary base for the adenine (A) present as template for the primer extension. This is true although the SF-ddCTP-519 is present at a higher concentration than in Example 2. No conclusions can be made with respect to whether A or G is incorporated, for these nucleotides although present, are not fluorescently labeled in the reaction. The lower panel of Figure 12 illustrates a significant level of misincorporation of SF-ddTTP-526 as a complementary base

discriminatory values given in Figure 7b). In these lanes, as in other lanes of the experiment, there is essentially no peak of unincorporated nucleotides present in the sample.

5

10

20

EXAMPLE 5

Aims:

- 1. To illustrate the use of a nucleic acid strand that is not bound to a solid support as the analyte strand.
- 2. To practice the method of this invention on a totally different biological sample than that used in Examples 1-4.

15 <u>Definition of the Nucleotide Position of Interest</u>:

In this example, the nucleotide position of interest is that of the lower strand, occupied by a circled G on Figure 14. The nucleotide sequence shown is a portion of the Wildtype Al gene of maize (Schwarz-Sommer et al., EMBO J. 6:287-294 (1987).

Definition of the Target Nucleotide Sequence:

In this example, the target nucleotide sequence
(TNS) is chosen as the 21 nucleotide sequence
25 (3'GACGAACTCCTAGCTCATCAC5') that immediately flanks the
nucleotide of interest such that the nucleotide position
of interest is the next contiguous nucleotide in the 3'
to 5' direction on that nucleic acid strand.

30 The oligonucleotide probe:

In this example, the oligonucleotide probe consists of the 21 nucleotide sequence 5' CTGCTTGAGGATCGAGTAGTG 3' (Primer C of Figure 14), and is perfectly complementary to the target nucleotide sequence defined

20

25

NaOH solution is carefully neutralized by addition of a few microliters of 0.5M HCl, monitoring the pH of the solution using pH paper. To this neutralized DNA sample (vol. aprox. 23 μ l), the following addition is made:

- 8.0 μl of 5X RT buffer (Invitrogen)
- 2.8 µl of 1% Triton X-10
 - 0.5 µl of 1 mM ddATP (unlabeled)
 - 0.5 µl of 1 mM ddTTP (unlabeled)
- 4.0 μl of 6.6 μM Biotinylated nested primer
- 8. The sample is incubated 95°C for 2 minutes, 37°C ninutes, and then placed on ice.
 - 9. The following additions are made:
 - $2 \mu l$ of 125 μM SF-ddCTP-519
 - $2 \mu l$ of 125 μM SF-ddGTP-505
- 15 1 μ l of Reverse Transcriptase (Invitrogen 10 μ/μ l)
 - 10. The sample is incubated 42°C 10 minutes.
 - 11. 15 μ l of Dynabeads (prepared as in step 1) are added and followed by a 37°C incubation for 15 minutes with intermitent shaking. This is to promote binding of the nested, biotinylated primer (containing fluorescent label from the primer extension reaction).
 - 13. The sample is magnetized for 4 minutes and unincorporated nucleotides present in the supernatant are removed.
 - 14. The final bead pellet is washed 3 times with 100 μ l TE (magnetizing each time to remove the buffer).
 - 15. The final bead pellet is resuspended in 5 μ l of FE (95% formamide, 25 mM EDTA).
- 30 16. 2 μl of this sample along with 1 μl of a smaller, control primer (Std) are heated for 2 min 95°C, before loading on a urea-polyacrylamide gel and electrophoresis on the Genesis 2000.

- 8.0 μ l of 5X Sequenase buffer (200 mM Tris pH 7, 100 mM MgCl2, and 250 mM NaCl)
- 2.8 µl of 1% Triton X-100
- 0.5 µl of 1 mM ddATP (unlabeled)
- 0.5 µl of 1 mM ddTTP (unlabeled)
- 4.0 μl of 6.6 μM Biotinylated oligonucleotide probe (primer C)
- c) In step 9, 1.5 μl of 100 mM Dithiothreitol is added (in addition to the fluorescent substrates SF-ddCTP-519 and SF-ddGTP-505), and 1 μl of 13 units/μl Sequenase Version II enzyme (a modified T7 DNA polymerase: US Biochemical Corp. US Patent 4,795,699) instead of the reverse transcriptase enzyme.
- d) In step 10, the labeling reaction is at 37°C for 15 10 minutes.

The results of Example 6 are shown in Figure 16. is seen that a single peak of incorporation appears, suggesting that the Sequenase II enzyme can also be used for the practice of this invention with no significant 20 3'-5' exonuclease activity. The green/red ration (=1.7) of this peak is as would be expected for a DNA sample that is heterozygous. That is, the calibration graph of Figure 7c indicates that the value of 1.7 is approximately equal distance between the expected values 25 for incorporation of SF-ddCTP-519 (green/red approximately 0.9) and that for incorporation of SF-ddGTP-505 (green/red approximately 2.4). Note that in this example, SF-ddATP-512 that gives a green/red ratio of approximately 1.6 is not included in the 30 reaction, thus the 1.7 ratio does not indicate the addition of an adenine.

In conclusion, in Example 6 it is determined that the nucleotide position of interest in the sample is

The chain-terminating nucleotide which extended the probe at the position complementary to the nucleotide of interest is detected and determined as shown in Example 1. The nucleotide of interest at position 500 is identified as the nucleotide complementary to the chain-terminating nucleotide which extended the probe in the labeling reaction. The presence and nature of a polymorphism can be determined by comparing the samples tested.

From the foregoing description, one skilled in the art can easily ascertain characteristics of this invention, and without departing from the spirit and scope thereof, can make various modifications of the invention to adapt it to various uses and conditions.

(B) TELEFAX: 302-892-7949

(2) INFO	RMATION FOR SEQ ID NO:1:	
(i)	SEQUENCE CHARACTERISTICS:	
	(A) LENGTH: 21 base pairs	
	(B) TYPE: nucleic acid	
	(C) STRANDEDNESS: double	
	(D) TOPOLOGY: linear	
(ii)	MOLECULE TYPE: DNA (genomic)	
(xi)	SEQUENCE DESCRIPTION: SEQ ID NO:1:	
CTGCTGCCCG	ACAACAGCAA T	21
(2) INFOR	MATION FOR SEQ ID NO:2:	
(i)	SEQUENCE CHARACTERISTICS:	
	(A) LENGTH: 21 base pairs	
	(B) TYPE: nucleic acid	
	(C) STRANDEDNESS: double	
•	(D) TOPOLOGY: linear	
(ii)	MOLECULE TYPE: DNA (genomic)	
(xi)	SEQUENCE DESCRIPTION: SEQ ID NO:2:	
1 mm 0 0 m 0 m 0 0		21
ATTGCTGTTG	TCGGGCAGCA G	21
(2) INFOR	MATION FOR SEQ ID NO:3:	
(i)	SEQUENCE CHARACTERISTICS:	
	(A) LENGTH: 26 base pairs	
	(B) TYPE: nucleic acid	
	(C) STRANDEDNESS: double	
	(D) TOPOLOGY: linear	
(ii)	MOLECULE TYPE: DNA (genomic)	
(xi)	SEQUENCE DESCRIPTION: SEQ ID NO:3:	
CAGACATTTG	AGAATCAAGT GAATCG	26

(A) LENGTH: 21 base pairs	
(B) TYPE: nucleic acid	
(C) STRANDEDNESS: double	
(D) TOPOLOGY: linear	
(ii) MOLECULE TYPE: DNA (genomic)	
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:	
CACTACTCGA TCCTCAAGCA G	21
(2) INFORMATION FOR SEQ ID NO:8:	
(i) SEQUENCE CHARACTERISTICS:	
(A) LENGTH: 21 base pairs	
(B) TYPE: nucleic acid	
(C) STRANDEDNESS: double	
(D) TOPOLOGY: linear	
(ii) MOLECULE TYPE: DNA (genomic)	
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:	
CTGCTTGAGG ATCGAGTAGT G	21
(2) INFORMATION FOR SEQ ID NO:9:	
(i) SEQUENCE CHARACTERISTICS:	
(A) LENGTH: 21 base pairs	
(B) TYPE: nucleic acid	
(C) STRANDEDNESS: double	
(D) TOPOLOGY: linear	
(ii) MOLECULE TYPE: DNA (genomic)	
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:	
ATTGCTGTTG TCGGGCAGCA G	21
(2) INFORMATION FOR SEQ ID NO:10:	
(i) SEQUENCE CHARACTERISTICS:	
(A) LENGTH: 43 base pairs	
(B) TYPE: nucleic acid	

(ii) MOLECULE TYPE: DNA (genomic)	
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:	
ATTGCTGTTG TCGGGCAGCA GG	22
(2) INFORMATION FOR SEQ ID NO:14:	
(i) SEQUENCE CHARACTERISTICS:	
(A) LENGTH: 43 base pairs	
(B) TYPE: nucleic acid	
(C) STRANDEDNESS: double	
(D) TOPOLOGY: linear	
(ii) MOLECULE TYPE: DNA (genomic)	
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:	
•	
GGATCCGCTT GCCCTCTACA TCCTGCTGCC CGACAACAGC AAT	43
(2) INFORMATION FOR SEQ ID NO:15:	
(i) SEQUENCE CHARACTERISTICS:	
(A) LENGTH: 43 base pairs	
(B) TYPE: nucleic acid	
(C) STRANDEDNESS: double	
(D) TOPOLOGY: linear	
<pre>(ii) MOLECULE TYPE: DNA (genomic) (xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:</pre>	
(X1) SEQUENCE DESCRIPTION: SEQ ID NO.13.	
ATTGCTGTTG TCGGGCAGCA GAATGTAGAG GGCAAGCGGA TCC	43
(2) INFORMATION FOR SEQ ID NO:16:	
(1) SEQUENCE CHARACTERISTICS:	
(A) LENGTH: 21 base pairs	
(B) TYPE: nucleic acid	
(C) STRANDEDNESS: double	
(D) TOPOLOGY: linear	
(ii) MOLECULE TYPE: DNA (genomic)	

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:19:	
ATTGCTGTTG TCGGGCAGCA GGATGTAGAG GGCAAGCGGA TCC	43
(2) INFORMATION FOR SEQ ID NO:20:	
(i) SEQUENCE CHARACTERISTICS:	
(A) LENGTH: 22 base pairs	
(B) TYPE: nucleic acid	
(C) STRANDEDNESS: double	
(D) TOPOLOGY: linear	
(ii) MOLECULE TYPE: DNA (genomic)	
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:20:	
GGATCCGCTT GCCCTCTACA TC	22
(2) INFORMATION FOR SEQ ID NO:21:	
(i) SEQUENCE CHARACTERISTICS:	
(A) LENGTH: 43 base pairs	
(B) TYPE: nucleic acid	
(C) STRANDEDNESS: double	
(D) TOPOLOGY: linear	
(ii) MOLECULE TYPE: DNA (genomic)	
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:21:	
GGATCCGCTT GCCCTCTACA TTCTGCTGCC CGACAACAGC AAT	43
(2) INFORMATION FOR SEQ ID NO:22:	
(i) SEQUENCE CHARACTERISTICS:	
(A) LENGTH: 45 base pairs	
(B) TYPE: nucleic acid	
(C) STRANDEDNESS: double	
(D) TOPOLOGY: linear	
(ii) MOLECULE TYPE: DNA (genomic)	

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:25:

TGCTGTTGTC GGGCAGCAGA AA

22

- (2) INFORMATION FOR SEQ ID NO:26:
 - (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 45 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: double
 - (D) TOPOLOGY: linear
 - (ii) MOLECULE TYPE: DNA (genomic)
 - (xi) SEQUENCE DESCRIPTION: SEQ ID NO:26:

GGATCCGCTT GCCCTCTACA TTTTCTGCTG CCCGACAACA GCAAT 45

- (2) INFORMATION FOR SEQ ID NO:27:
 - (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 603 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: double
 - (D) TOPOLOGY: linear
 - (ii) MOLECULE TYPE: DNA (genomic)
 - (xi) SEQUENCE DESCRIPTION: SEQ ID NO:27:

CAGACATTTG AGAATCAAGT GAATCGTATT CTCAATGATG CTCGAGACAA AACTGGCTCC 60 TCTGCACAGA AATCCCTCTC TGAATATAAC AACTTCAAGT CTATGGTGGT GTCTGGAGCC 120 AAGGGTTCCA AGATCAACAT CTCCCAGGCA AGATGCTTCA TTTTCCAGAT ATGTGGCCTA 180 TACCAGAGTT TGTAAAGAGG ATGGTATGTA CATGTTTTGG TGTGAGGAAA GATGGAAAAA 240 ATAGTAGGGA ATTGTCACCA CCACCACCAC TGCTGCAGTG TCATGGCTTG AAACAAGATT 300

CTTGGCTCCA GACACCACCA TAGACTTGAA GTTGTTATAT TCAGAGAGGG ATTTCTGTGC 540

AGAGGAGCCA GITTIGICIC GAGCATCATI GAGAATACGA TICACTIGAT TCICAAATGI 600

CTG 603

- (2) INFORMATION FOR SEQ ID NO:29:
 - (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 60 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: double
 - (D) TOPOLOGY: linear
 - (ii) MOLECULE TYPE: DNA (genomic)
 - (xi) SEQUENCE DESCRIPTION: SEQ ID NO:29:

CCCCCCTTA GGTCATTGCT GTTGTCGGGC AGCAGAATGT AGAGGGCAAG CGGATCCCAT 60

- (2) INFORMATION FOR SEQ ID NO:30:
 - (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 60 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: double
 - (D) TOPOLOGY: linear
 - (ii) MOLECULE TYPE: DNA (genomic)
 - (xi) SEQUENCE DESCRIPTION: SEQ ID NO:30:

ATGGGATCCG CTTGCCCTCT ACATTCTGCT GCCCGACAAC AGCAATGACC TAAGGGGGGG 60

- (2) INFORMATION FOR SEQ ID NO:31:
 - (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 60 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: double
 - (D) TOPOLOGY: linear

- (2) INFORMATION FOR SEQ ID NO:34:
 - (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 295 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: double
 - (D) TOPOLOGY: linear
 - (ii) MOLECULE TYPE: DNA (genomic)
 - (xi) SEQUENCE DESCRIPTION: SEQ ID NO:34:

CCTGCAGATG TACTTCGTGT CTAAAACCCT GGCGGAGAAG GCGGCCCTGG CGTACGCGGC 60 GGAGCACGGC CTGGACCTGG TCACCATCAT CCCGACGCTC GTGGTCGGCC CGTTCATCAG 120 CGCGTCCATG CCGCCCAGCC TCATCACCGC GCTGGCGCTC ATCACGGGGA ACGCGCCGCA 180 CTACTCGATC CTCAAGCAGG TGCAGCTCAT CCACCTCGAC GACCTCTGCG ACGCCGAGAT 240 CTTCCTCTTC GAGAACCCGG CCGCGGCCGG GCGCTACGTC TGCTCCTCGC ACGAC

295

- 6. The method of Claim 1 wherein the probe is extended enzymatically.
- 7. The method of Claim 1 wherein the added chain terminating nucleotide is determined by detecting the presence of a signal generator.
 - 8. The method of Claim 1 wherein the nucleic acid analyte is single stranded.
- 9. The method of Claim 1 wherein the nucleic acid analyte is immobilized on a solid support.
- 10. The method of Claim 1 wherein the probe is immobilized on a solid support.

- 11. A kit for identification of a nucleotide of interest in a nucleic acid analyte, comprising:
- a) a probe which comprises a primer sequence


 20 complementary to the nucleic acid analyte and capable of
 binding the nucleic acid analyte with sufficient
 specificity to form a stable hybrid adjacent to the
 nucleotide of interest;
- b) a plurality of reporter labeled chain25 terminating nucleotide triphosphates; and
 - c) a primer-dependent nucleic acid polymerase.
- 12. A method of identifying a nucleotide of interest present at a defined position in a nucleic acid analyte, comprising:
 - a) contacting the nucleic acid analyte with a probe such that annealing takes place adjacent to the nucleotide of interest;


- 20. The method of Claim 12 wherein the nucleic acid analyte is immobilized on a solid support.
- 21. The method of Claim 12 wherein the probe is immobilized on a solid support.
 - 22. A kit for identification of a nucleotide of interest in a nucleic acid analyte, comprising:
- a) a probe which comprises a primer sequence

 10 complementary to the nucleic acid analyte and capable of
 binding the nucleic acid analyte with sufficient
 specificity to form a stable hybrid adjacent to the
 nucleotide of interest;
- b) at least one of reporter labeled chain terminating nucleotide triphosphates; and
 - c) a primer-dependent nucleic acid polymerase.


20

25






6/23 FIG.3



HYBRIDIZE NESTED PRIMER

- + FLUORESCENT ddNTP(s)
- + REVERSE TRANSCRIPTASE







FIG.7A

GREEN TO RED RATIO FOR FLUORESCENT NUCLEOTIDES

DETECTED USING GEL ELECTROPHORESIS:



DETECTED IN CAPILLARY:



FIG.7C




FIG.8B

CONTINUED FROM FIG. 8A

5125		
7	CGTGATAAAGACGGTATTTAAG	5394
	5' prode A 3' CCCCCCTTAGGTCATGTTGTCCCATCCCAT	
2333	GGGGGGGAATCCAGTAACGACAACAGCCCGTCGTCTTACATCTCCCGTTCGCCTAGGGTA	5454
7 Y	TIGGATICAAGCATCGGACTCTTCCTCACTTTATCAAGGATGATTATGGTCCTGAGAGCC	
) - -	AACCTAAGTTCGTAGCCTGAGAAGGAGTGAAATAGTTCCTACTAATACCAGGACTCTGG	5514
	GAG PRIMER 2	
5515	5515 5517	
	STC STC	

16/23 FIG.10A




FIG. 11






FIG. 13





r avs	SIFICATION OF SUBJ	ECT MATTER (If several classific	ation symbols apply, indicate a(l)6			
Accordin	g to International Pater	t Classification (IPC) or to both Nati	ional Classification and IPC			
Int.C	1. 5 C12Q1/68	}				
İ		•				
II. ETEL I	S SEARCHED					
4. 1122	75 SEARCHED					
	·	Minimum D	ocumentation Searched			
Classific						
Int.C1		0100				
1116.61	i. 3	C12Q				
		Documentation Searched	other than Minimus Documentation			
		to the Extent that such Docum	sents are Included in the Fleids Searched			
M DOG:						
	MENTS CONSIDERE					
Category *	Citation of Do	coment, 11 with indication, where app	ropriate, of the relevant passages 12	Relevant to Claim No.13		
X	EP,A,0 4	12 883 (BERTIN & CIE	E) 13 February 1991	1-22		
	see the	whole document				
,	WIGH ETA	40130 0505(DA)				
		ACIDS RESEARCH.	107011 1170071171 110	1-22		
į	page 367	no. 12, 1990, ARLIN	IGION, VIRGINIA US			
ĺ			edan tashadaya 6			
	the deter	KOLOV: 'Primer exten ction of single nucl	sion technique for			
	DNA'	seron or single nucl	eocide in genomic			
1		the application				
	see the	whole document				
1		,				
1			-/			
- 1						
- 1			,			
- 1						
j			}			
ł						
- 1		•				
* Special c	extegories of cited documents					
"A" docum	ment defining the soner	I state of the art which is not	"I" later document published after the internati or priority date and not in conflict with the	anelication but		
(300)	considered to be of particular relevance					
"L" earne	or document but publishe Late	ed on or after the international	"X" document of particular relevance; the ciaim	ed invention		
"L" docum	nest which may throw de	subts on priority claim(s) or	cannot be considered novel or cannot be con involve an inventive step	nridered to		
CHILD	or on east should lette	publication date of another a (as specified)	"Y" document of particular relevance the civins	od invention		
"O" decan	ment referring to an eral	disclorure, use, exhibition or	cannot be considered to involve an inventive document is combined with one or more other.	er sich dock		
T' tom	PORT Published ories to t	he international filing date but	ments, such combination being obvious to a in the art.	person skilled		
inter 1	then the priority date cir	ind	"A" document member of the same patent family	,		
CENTRA	CATION					
te of the Ac	tual Completion of the f	storactional Search	Date of Mailing of this International Search	Resert		
18 JUNE 1992			•			
) <u> </u>	3 0. 06. 92			
ractional S	earching Authority		. Signature of Authorized Officer			
	EUROPEAN	PATENT OFFICE	MOLINA GALAN E.	1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1		
<u>.</u>		• • • • • • • • • • • • • • • • • • • •	Linkster BUTHE E.	W. T.		
			_1			

Pour PCT/ISA/210 (second short) (Jenney 1981

ANNEX TO THE INTERNATIONAL SEARCH REPORT ON INTERNATIONAL PATENT APPLICATION NO. US 9201691 SA 57791

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report. The members are as contained in the European Patent Office EDP file on

The European Patent Office is in no way liable for those particulars which are merely given for the purpose of information, 18/06/92

Patent document cited in search report	Publication date		Patent family member(s)		Publication date
EP-A-0412883	13-02-91	FR-A- AU-A- WO-A-	2650840 6180190 9102087	11	-02-91 -03-91 -02-91
WO-A-8909283	05-10-89	US-A- AU-A-	4971903 3354889		-11-90 -10-89
WO-A-9106678	16-05-91	EP-A-	0450060	09-	10-91